|Home | About | Journals | Submit | Contact Us | Français|
To determine the frequency and types of respiratory viruses circulating in Boston long-term care facilities (LTCFs) during a 3-year period.
Thirty-three Boston-area LTCFs over a 3-year period.
Residents of long-term care who had previously participated in a trial of vitamin E supplementation and had paired serum samples available for viral analysis.
Viral antibody titers to eight respiratory viruses (influenza A and B, respiratory syncytial virus (RSV), parainfluenza virus serotype three (PIV-3), PIV-2, human metapneumovirus (hMPV), and coronaviruses 229E and OC43) were measured using enzyme immunoassay at baseline and 53 weeks. Infection was defined as a more than quadrupling of viral titers. Clinical data on respiratory illnesses were collected throughout the study period.
A total of 617 persons were enrolled in the trial. Of these, 382 (62%) had sera available for viral analysis. A total of 204 viral infections were documented in 157 subjects. Serological responses to all eight viruses were documented, with hMPV (12.8%) and coronavirus 229E (10.5%) being the most common and PIV-2 (2.4%) the least common. The occurrence of bronchitis (P = .007), pneumonia (P = .02), and any lower respiratory tract infection (P = .002) was significantly associated with having a viral diagnosis.
A wide range of respiratory viruses cocirculates in LTCFs and contributes to respiratory illness morbidity in these populations.
Respiratory tract infections are a major cause of morbidity and mortality in long-term care facilities (LTCFs).1 Awide range of bacterial and viral pathogens has been documented in nursing home settings, although the relative contribution of specific pathogens is not well defined.2,3 Influenza and respiratory syncytial virus (RSV) are now accepted as significant pathogens in this population, but the roles of other viruses such as the newly described human metapneumovirus (hMPV) are largely unexplored.4 Residents of LTCFs are at risk for nosocomial spread of respiratory viruses, and outbreaks of respiratory illness are not uncommon.5 Although infections with these pathogens in young adults are generally mild, serious complications may occur in frail elderly persons.6 Thus, residents of nursing homes are considered target groups for antivirals and vaccines. Although influenza remains the most important viral respiratory pathogen in this population, determining the types and frequencies of other viruses leading to lower respiratory infections (LRIs) in nursing homes may have importance for future studies of preventative measures and therapeutics. As a first step, serum samples that were available from a vitamin E supplementation trial conducted in a large number of LTCFs were analyzed for evidence of recent infection with eight common respiratory viruses, and viral diagnoses were correlated with the occurrence of respiratory illnesses.
Study participants were recruited from 33 LTCFs in the Boston, Massachusetts, area over a 3-year period from 1998 to 2000.7 Inclusion criteria were aged 65 and older; life expectancy greater than 6 months; not room bound; and absence of active cancer, tube feeding, urethral catheters, tracheostomy, chronic ventilator dependence, or long-term steroid use. In addition, a serum albumin of at least 3.0 g/dL and willingness to receive influenza vaccine were required. The Tufts New England Medical Center institutional review board approved the study. All participants or their legal guardians provided informed consent.
During the 3 years of study, 617 volunteers were enrolled in a vitamin E supplementation trial for a 52-week intervention period. A serum sample was collected at the time of enrollment (April–August) and at Week 53, after 1 year of supplementation. Investigators trained study nurses to identify relevant respiratory symptoms and perform focused physical examinations, and prospective surveillance for respiratory illnesses was conducted throughout the year. Data from the nursing home medical records and findings by study nurses were used to classify respiratory illnesses. Respiratory tract infections were categorized according to standard definitions and included common cold, influenza-like illness, pharyngitis, otitis media, sinusitis (defined as upper respiratory infection (URI)) and acute bronchitis and pneumonia (defined as LRI).8 Patient samples were not collected at the time of illness for diagnostic microbiology.
Enzyme immunoassay (EIA) was performed to detect viral-specific immunoglobulin G for eight respiratory viruses (influenza A and B, respiratory syncytial virus (RSV), parainfluenza virus serotype three (PIV-3), PIV-2, human metapneumovirus (hMPV), and coronaviruses 229E and OC43) according to published methods.9–12 Briefly, antigens were produced from virally infected whole-cell lysates for all viruses except RSV. Purified viral surface glycoproteins were used as antigen for RSV EIA, according to published methods.11 Paired serum samples were screened at a single dilution, and those showing a 1.5 times or more greater optical density reading from acute to convalescent specimens were further tested using full dilution to determine antibody titer. Serial two-fold dilutions of each sample were tested in duplicate, and infection was defined as a more than quadrupling in antibody from baseline to Week 53. Because PIV-1 and PIV-3 antibodies cross-react, infection with these viruses cannot be distinguished serologically. Therefore, a serological response to PIV-3 antigen is designated PIV-1/3.
All analyses were performed using SAS for Windows, version 9.1.3 (SAS Institute, Inc., Cary, NC). Chi-square and Fisher exact tests were used to compare proportions. Means were compared using the Student t-test for independent samples. The association between clinical illness (yes or no) and number of viral infections diagnosed (0, 1, or 2) was assessed using the Mantel-Haenszel chi-square statistic for linear association as implemented in SAS PROC FREQ.
A total of 617 persons were enrolled in the trial. Of these, 452 (73%) completed the study, and 382 (62%) had paired sera available at baseline and 53 weeks for viral analysis. Differences between the baseline characteristics of those who did and did not undergo viral testing were not statistically significant (data not shown). Demographics and underlying medical conditions were also similar for the group with documented viral infection and those who tested negative for viral infection (Table 1).
Overall, 204 viral infections were documented in 157 subjects. Thus, 41% of participants had at least one viral infection during the 1-year study period. One hundred seventeen subjects had one infection, 34 had two infections, five had three infections, and one had evidence of four viral infections. Serological responses to all eight viruses were documented in the study patients, with hMPV and coronavirus 229E being the most common and PIV-2 the least frequent (Table 2). Although the activity of individual viruses varied according to year studied, all viral infections were identified each year. Displayed graphically as cases per facility in each year (Figure 1), these data indicate the complex nature of viral respiratory disease in nursing homes. With the exception of two facilities in which 42% (1999) and 28% (2000) of residents tested were positive for hMPV and one facility with a 36% positive rate for influenza A during 1999, there did not appear to be predominance of a single pathogen within a nursing home. Rather, a multitude of pathogens circulating throughout the facilities during all 3 years was observed.
Because sera were not collected immediately surrounding each illness, a specific etiology could not be assigned to an individual illness, but analysis of the clinical data showed a significant association between serological diagnosis of a viral infection and the occurrence of bronchitis (P = .007), pneumonia (P = .02), any LRI (P = .002), and any respiratory infection (P = .02) but not URI (P = .17) according to Mantel-Haenszel chi-square.
This report demonstrates the wide range of respiratory viruses that circulate in LTCFs. Previous reports of viral disease in these populations have focused primarily on outbreaks of specific viruses, most often influenza.7,13–17 There have also been a number of prospective studies that have examined the role of other respiratory viruses such as RSV and parainfluenza in nursing homes, but most have been limited to a single season or institution.2,11,18–20 This study is unique in that 33 nursing homes over a 3-year period were under surveillance, and evaluation of eight different viral infections was undertaken. Although this trial was not designed to examine the specific microbiological etiology of respiratory illnesses, the collection of blood at baseline and 1 year provided an opportunity for serological diagnosis of multiple viral infections over time. In addition to the well-recognized pathogens influenza and RSV, infections due to hMPV, coronaviruses OC43 and 229E, and parainfluenza viruses were identified throughout the study period. Rather than large outbreaks of single pathogens, a veritable cornucopia of viruses circulated in individual nursing homes each year.
A rise in viral-specific antibody according to EIA remains sensitive and specific for detection of infection for most respiratory viruses in elderly people, even when compared with new molecular methods such as reverse transcription polymerase chain reaction (RT-PCR).9,21 Several exceptions are worth noting, one being influenza, in which response to vaccination may complicate the serological diagnosis of infection. In the current study, 24 and 19 residents were diagnosed with influenza A and B, respectively. None of the subjects infected with influenza A showed antibody rises to influenza B, and vice versa, suggesting that antibody rises were not vaccine induced. In addition, vaccine effect was less likely, because serum samples were obtained 7 to 9 months after immunization, when vaccine induced antibody has typically decreased to near baseline.22 Another limitation of serology for viral diagnosis is the inability to identify rhinovirus. Rhinovirus is a ubiquitous pathogen that has been shown to cause outbreaks of respiratory disease in nursing homes, but serological diagnosis is not possible, because multiple serotypes exist.23 Because rhinoviruses are a frequent cause of the common cold, it is not surprising that no association was found between URI and serological viral diagnosis.
Presently, there are limited data in elderly people on the newly described virus hMPV and its role as a cause of illness in LTCFs. Outbreaks of hMPV infection with significant morbidity and mortality in LTCFs have been reported in the United States, Canada, and Japan.16,24 In each report, diagnosis was made using RT-PCR, and the number of documented cases was small. In this study, hMPV was the most common infection diagnosed, accounting for 24% of the documented viral infections. Asymptomatic serological infection has been described in 9.5% of young and 1.5% of elderly adults.9 The clinical syndromes were not assessed in the current study, and therefore the true effect of hMPV could not be assessed. However, the frequency of infection indicates that prospective studies of hMPV in LTCFs are needed.
Similar to hMPV, coronaviruses are difficult to detect using standard viral cultures. Thus, few data are available on the effect of these viruses in long-term care. In a prospective study of 11 nursing homes in the United Kingdom using serology for diagnosis, 11% of acute respiratory infections were due to coronavirus OC43 or 229E.18 Outbreaks of respiratory illness due to coronavirus OC43 mimicking influenza have also been described in nursing homes.25 Coronaviruses OC43 and 229E were common in the current study, accounting for 6% and 11% of infections, respectively. Two new strains of human coronaviruses have recently been identified, NL63 and HKU1, and will require further study to determine whether these viruses are also important pathogens in this population.26,27
The current study demonstrates the complex nature of respiratory tract infections in LTCFs. Influenza infection was identified in 11% of residents, which confirms the need for improved influenza vaccines in this population, yet the broad range of other viruses circulating each year was impressive, underscoring the importance of viral-specific diagnosis during outbreak investigations or clinical trials of vaccines or antivirals. These data should provide useful information for those wishing to pursue clinical trials related to respiratory viral infections in nursing home populations.
The authors wish to thank Edward E. Walsh, MD, for his thoughtful review of the manuscript and the staff of the Metabolic Research Unit and Nutritional Evaluation Laboratory of Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University and the participating nursing homes for help in recruitment of subjects and analysis of blood micronutrients.
Sponsor's Role: The sponsor provided the funding for the original vitamin E study but did not provide funds for virologic testing or analysis.
Author Contributions: Dr. Falsey analyzed the viral data and wrote the manuscript. Dr. Dallal assisted with the analysis of data and reviewed and had a final say about the manuscript. Maria Formica and Gloria Andolina performed the viral assays and assisted with analysis of the viral data. Dr. Hamer was involved in the conceptualization of the study design, was responsible for data acquisition, and assisted with data interpretation and editing of the final manuscript. Lynette Leka was responsible for data acquisition. Dr. Meydani had full access to all of the data in the study and was responsible for the integrity of the data and the accuracy of the data analysis, as well as its acquisition. Dr. Meydani was responsible for the study concept and design and interpretation of study findings and assisted in the drafting and final editing of the manuscript.
Conflict of Interest: Dr. Falsey has received research grants from Sanofi-pasteur. She serves on the advisory board for Quidel Inc. and has consulted with Sanofipasteur, Glaxo-Smith Kline, Alnylam, Medimmune, and Merck and has received received honoraria. Dr. Hamer is on the speaker's bureau for Glaxo Smith Kline and owns shares of Inverness Medical Innovations, Inc., a company that makes respiratory diagnostics products. Dr. Meydani has funding in this area of study from the U.S. Department of Agriculture, National Institute on Aging (NIA), and Roche (for provision of the supplements for the study). This work was supported by NIA, National Institutes of Health Grant 1R01-AG13975 and U.S. Department of Agriculture (USDA) agreement 58-1950-9-001. The study was also supported by HRCA/Harvard Research Nursing Home PO1 AG004390 to Dr. Lipsitz, which facilitated recruitment of subjects and conduct of the study at Hebrew Rehabilitation Center.